Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$1.30 USD
-0.08 (-5.80%)
Updated May 30, 2024 03:06 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 201 - 220 ( 395 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
2017 Guidance Confirmed; Potential Partnerships of Three Assets in 2017
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Powerful Efficacy, Well-Tolerated and Low Abuse Potential; PT to $31
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Progress and Investment into NKTR-214 Continues; Reiterate Buy, $23 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Healthcare - Innovations in Oncology Corporate Access Day Recap
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Comprehensive Review of NKTR-214?s Phase 1/2 Study Provided At SITC
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Q3 In Line; NKTR-214 Picture is Filling In; 4 Ph3''s by Q1''17
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M